The initial phase of the HyperCell project focused on establishing the groundwork for integrating hyperpolarized metabolites with microscale Nuclear Magnetic Resonance (NMR) technology, targeting metabolic analysis of small-volume samples like single cells and embryos. NVision developed and carried out a controlled dilution method in order to adapt its existing hyperpolarized pyruvate solution to a concentration in which cells and embryos would be viable. Additionally, the team expanded its existing hyperpolarization capabilities beyond pyruvate to α-ketoglutarate, another sugar that could be employed for metabolic sensing. Annaida developed advanced micro-NMR sensor prototypes suitable for volumes down to 1 nL. They sensor head was redesigned for successful integration into standard benchtop NMR systems, including an easy micro-sample loading mechanism. This effectively demonstrated usability and proved the ability to increase sensitivity and decrease the needed sample volume compared to standard benchtop NMR capabilities. To prepare for the eventual introduction of hyperpolarized metabolites into these systems, NVision developed a reliable dual-syringe pump syringe prototype. This will allow for controlled injection of the metabolites as well as precise, custom adaptations to the system to include additional cell-sustaining nutrients if needed. An initial market analysis was also performed to identify key stakeholders, risks and opportunities, potential areas of impact, and to develop a tech to market plan. This tech to market plan was developed to ensure that the new technology is properly introduced to achieve its highest potential impact.
